Adjusted EBITDA reached $76M for Q2 2026, with revenue up 4% year-over-year and strong RCM collections, improved payer mix, and higher acuity offsetting lower volumes. Full-year EBITDA guidance is reaffirmed, and share repurchases continue, supported by a strong balance sheet.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.